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Determinants of outcome following surgery for oral 1 
squamous cell carcinoma 2 
 3 
Abstract summary 4 
The recent changes in incidence and prevalence of oral squamous cell 5 
carcinoma in relation to gender and age mirror the changing patterns of 6 
exposure to tobacco and alcohol, the main aetiological agents.  Most cases of 7 
oral cancer are managed by surgery, often combined with radiotherapy. 8 
Histopathological assessment of the resection specimen provides information 9 
vital for post-operative management and prognosis. This review considers the 10 
full range of histological determinants of outcome in relation to the primary 11 
oral tumour and any metastatic involvement of the cervical lymphatic system, 12 
together with an outline of more general patient factors that may also impact 13 
on morbidity and mortality rates.    14 
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Introduction 25 
The incidence of oral squamous cell carcinoma (SCC) varies worldwide and 26 
rates for the UK and the USA are increasing, and currently estimated as 10 27 
cases per 100,000 population per annum [201]. The highest age standardised 28 
rates (over 20 per 100,000 population) are reported in parts of Europe and 29 
south central Asia [201]. In high-incidence countries such as Sri Lanka, India, 30 
Pakistan and Bangladesh, oral cancer is the most common cancer in men and 31 
may account for up to 30% of all new cases of cancer compared to 3% in the 32 
UK and 6% in France [201]. 33 
The 5-year disease specific survival has improved slightly but still remains 34 
around 50% [202]. Surgery is the favoured treatment option for most patients 35 
[1] and has the advantage of providing a surgical specimen for detailed 36 
pathological staging on which the decisions on the need for adjuvant therapy 37 
(usually radiotherapy) and more accurate prognostication can be made. In 38 
recent years, reconstructive surgery has improved morbidity but survivors still 39 
face aesthetic [2] and functional problems [3].  This review considers the 40 
factors that determine outcome following surgery for oral cavity tumours, 41 
UICC ICD-O C00, C02-C06 [4]. General and clinical factors related to survival 42 
will be outlined first, followed by an account of histopathological factors which 43 
are, by far, the more important. Surgical treatment involves neck dissection in 44 
most patients and hence, the account considers features of both primary and 45 
metastatic disease. All the data discussed concerns patients who were 46 
managed by primary surgery without prior chemotherapy, radiotherapy or 47 
chemoradiation.    48 
 49 
1 General and clinical factors 50 
1.1 Age 51 
In a comprehensive analysis of survival reported by a regional maxillofacial 52 
surgery unit in the North-West region of England [ 5], patients aged 75 years 53 
or over were found to have a worse overall and disease specific 5-year 54 
survival probably due to increased co-morbidity and inability to withstand 55 
major surgery and radiotherapy. Several studies [6, 7] have shown an 56 
improved survival in patients < 65 years but there was no evidence of better 57 
survival in stage-matched younger (50-69) and older (>70 yrs) patient groups 58 
in the study of Bhattacharyya [8]. Current evidence [9-12] suggests that young 59 
age at presentation (<40 years) is not an adverse prognostic factor.   60 
 61 
1.2 Gender 62 
Until recently, females were thought to have a better prognosis than males 63 
[13, 14] but gender was not a significant factor in the study of Rogers et al [5] 64 
and there were no prognostic differences in a recent case-matched study by 65 
Garavello et al [15].    66 
 67 
1.3 Race 68 
Controlling for stage and treatment, black patients demonstrate poorer overall 69 
and disease-specific survival [16, 17]. One study [7] has suggested advanced 70 
stage at presentation accounts for poorer outcomes among black patients. 71 
Other studies have, however, shown that lower survival amongst Blacks may 72 
be associated with less access to, and underutilisation of, healthcare 73 
resources [18, 19]. 74 
 75 
1.4 Co-morbidity 76 
Alcohol and tobacco smoking, the primary aetiological agents for oral cancer 77 
[20, 21], cause other chronic conditions and may contribute to the high 78 
prevalence of co-morbidity and poor survival of patients [21-27]. Additionally, 79 
co-morbidities may have consequences for reconstruction and rehabilitation 80 
by affecting the success of vascularised free-flaps [28, 29]. Around one-fifth of 81 
head and neck cancer patients suffer moderate to severe co-morbidity [5, 26] 82 
with a significant effect on  survival rates [23, 27] even when controlled for age 83 
and stage [26].    84 
 85 
1.5 Risk factors/lifestyle 86 
Cancer-free survival is worse in cases not related to smoking or alcohol 87 
exposure [10, 30] and this may reflect dietary [31], genetic and immunological 88 
differences [32-34]. Continued use of aetiological agents including tobacco, 89 
betel quid and alcohol is related to the development of second primary 90 
tumours [9].  HPV is widely reported to be an aetiological factor in a proportion 91 
of oropharyngeal squamous cell carcinomas and appears to be associated 92 
with a more favourable prognosis [35-37]. At oral cavity sites, firm conclusions 93 
have yet to be drawn regarding the importance of HPV in both pathogenesis 94 
and prognosis [38].   95 
 96 
 97 
1.6 Socio-economic 98 
Increased incidence of, and mortality from, oral cancer is related to material 99 
deprivation, particularly in males [39]. Whether social deprivation per se or 100 
behavioural differences in terms of smoking and alcohol use and poor diet are 101 
to blame is uncertain [40]. In terms of delayed presentation, Rogers et al [41] 102 
found no correlation with deprivation whereas others [7] report advanced 103 
stage at presentation in patients with low income.  104 
 105 
1.7 Psychological factors including support 106 
Single / divorced / widowed patients and those who do not have religious 107 
beliefs reportedly have lower survival [42].  108 
 109 
2 Histopathological factors 110 
2.1 Primary tumour 111 
2.1.1 Site 112 
More posteriorly located tumours have a lower 5 year survival [43]. Possible 113 
explanations include later stage at presentation, increased difficulty in 114 
achieving clear surgical margins and increased metastases that frequently 115 
involve multiple anatomical levels and may be bilateral [44, 45]. In tongue, 116 
retromolar and oropharyngeal tumours, 59-64% had nodal metastasis at initial 117 
surgery compared to only 22% of buccal tumours [46]. The same study [46] 118 
also shows different survival patterns with 38-41% of retromolar, 119 
oropharyngeal and lateral tongue patients dying of / with oral SCC compared 120 
to only 10-17% of patients with floor-of-mouth / buccal tumours.  121 
2.1.2 Clinical and pathological T stage and tumour dimensions 122 
Clinical and pathological TNM staging (TNM and pTNM, respectively) [4] uses 123 
the same criteria for categorising T stage based on tumour greatest surface 124 
dimension for categories T1-T3, and involvement of specific structures (such 125 
as bone and skin) for T4, and are major determinants of outcome [5, 47, 48]. 126 
The pT stage is the more accurate prognosticator as the clinical measurement 127 
frequently underestimates the true extent since tumour often undermines 128 
intact mucosa and satellites nodules cannot be detected by palpation or 129 
current routine imaging procedures. Distinction between dysplasia and 130 
invasive carcinoma at the mucosal periphery, and the occurrence of multifocal 131 
invasive carcinoma, are further potential sources of error [49]. In addition, 132 
differentiating between hyperplastic high-grade dysplastic lesions and 133 
microinvasive carcinoma is a continuing diagnostic challenge and discussed 134 
by Woolgar and Triantafyllou [50]. Reliance on an intact basement membrane 135 
is problematic as this can be disrupted by the subepithelial inflammatory 136 
reaction that may accompany dysplasia. Cross-cutting of irregularly 137 
hyperplastic rete processes can also lead to a false impression of invasive 138 
islands. However, despite the practical difficulties in accurately measuring the 139 
T diameter, it is well established that T stage at presentation is correlated with 140 
local recurrence, lymph node metastasis and poor survival [44, 46, 47, 51].  141 
Recent studies [48, 52-56] show that tumour thickness is a more significant 142 
prognosticator on multivariate analysis than tumour T stage / surface 143 
dimension, particularly in T1 and T2 tumours [53]. Although the risk of nodal 144 
metastasis is a function of thickness as a continuum rather than an all-or-145 
nothing phenomenon, the concept of a critical thickness is a useful one and 146 
overall in the oral cavity, a tumour 4 mm thick has a fourfold increased risk 147 
[57]. However, regional differences within the oral cavity exist and in the floor 148 
of mouth, depth of 1.5mm may be significant due to the plentiful thin-walled, 149 
superficial lymphatic vessels [58]. 150 
2.1.3 Histological grade 151 
The current UICC and WHO recommended tumour grading system [4, 59] is 152 
based on Broders’ original classification [60] and defines three categories: 153 
well, moderate and poorly differentiated. Tumour heterogeneity and inter-154 
observer variability are well known problems and may explain the lack of 155 
correlation of grade with outcome in many studies [52, 53].  In addition, 156 
grading is poorly discriminating since the vast majority of tumours are Grade 2 157 
(moderately differentiated) [59].   158 
2.1.4 Multifactorial and invasive front histological grading 159 
Systems in which various histological features are assigned a numerical score 160 
[61-63] have been devised in an attempt to overcome the deficiencies in UICC 161 
/ WHO grading. Problems of tumour heterogeneity and sampling still exist but 162 
the intention here is to grade the most severely atypical areas at the deepest 163 
aspect of the tumour using more strictly defined criteria. Several workers [44, 164 
62, 64, 65] have found invasive front multifactorial grading to be predictive of 165 
recurrence, metastasis and survival although inter-observer variability remains 166 
an important shortcoming [63]. The single most important factor is pattern of 167 
invasion [56, 63, 64, 66, 67] with a tumour having a poorly-defined invasive 168 
front composed of small islands and cords of keratinocytes more likely to 169 
metastasise than a circumscribed tumour with bulbous islands and broad 170 
cords. In an attempt to improve standardisation, the Royal College of 171 
Pathologists, UK, (RCPath) Guidelines [68] suggest two categories: cohesive 172 
and non-cohesive comprising patterns 1 / 2 and 3 / 4, respectively, in the 173 
original description of Anneroth et al [61] and Bryne et al [62].  174 
2.1.5 Lymphovascular invasion 175 
When strict criteria are applied – isolated, or clusters of, tumour cells within 176 
endothelial-lined channels or invasion of the media of a vessel with ulceration 177 
of the lumen – several studies [44-46] have demonstrated a positive 178 
correlation with multiple adverse histological features (tumour site, diameter, 179 
thickness, perineural invasion, pattern at invasive front) and also with nodal 180 
metastasis, the status (closeness) of the resection margin and recurrence. 181 
Lymphovascular invasion is a factor influencing survival on univariate analysis 182 
[46, 69].  183 
2.1.6 Perineural invasion 184 
Studies [5, 40-42, 56, 67, 70, 71] have repeatedly shown infiltration of nerve 185 
or perineurium at the advancing front of tumours relates not only to size and 186 
depth of the primary tumour but also to marginal status, presence of nodal 187 
metastasis, and survival. When present, the 5-year disease specific survival 188 
dropped from 81% to 55% on univariate analysis in a recent study [5]. Lip 189 
cancer generally has a much better prognosis than intra-oral cancer [202]. 190 
However, it is significant that perineural invasion in lip tumours is highly 191 
predictive of lymph node metastasis, aggressive clinical course and reduced 192 
survival [202]. 193 
2.1.7 Bone involvement 194 
Distinguishing between the erosive and invasive types [72] is important in the 195 
histological appraisal of bone involvement since the latter is predictive of 196 
recurrence and survival even after taking into account other soft tissue 197 
prognosticators. The current pTNM staging [4] does not consider the type of 198 
involvement with erosive tumours still classified as pT4, pstage IVA. This is 199 
unfortunate since gingival / alveolar carcinomas frequently show bone erosion 200 
by virtue of their position yet metastasise infrequently, and, hence, as 201 
independent studies have shown [72, 73], do not deserve their pT4 status and 202 
implied poor prognosis. The high proportion of gingival / alveolar carcinomas 203 
may explain the lack of an association between bone invasion and prognosis 204 
in the two studies by O’Brien et al [74, 75]. 205 
2.1.8 Skin involvement 206 
This is a particularly adverse finding with reports of median survival of only 207 
seven months in a study by Cole and McGuirt [76]. 208 
2.1.9 Histological subtypes of squamous cell carcinoma  209 
These are reviewed in an article by Pereira et al [77] and listed in Table 1. 210 
Verrucous carcinoma is a well-differentiated subtype that involves connective 211 
tissue on a broad, pushing (compressive) front and rarely leads to lymph node 212 
metastasis [59]. When arising in close proximity to bone, erosion is more likely 213 
than invasion. Approximately one-fifth of verrucous carcinomas are found to 214 
harbour foci of conventional squamous cell carcinoma. The prognosis is then 215 
comparable to that of the higher grade or conventional tumour [59]. Two 216 
subtypes of SCC reported to have a particularly poor prognosis are basaloid 217 
SCC and adenosquamous carcinoma [78, 79]. Extensive local spread and 218 
frequent early lymph node metastasis are likely reasons as well as a 219 
tendency, particularly for the basaloid variant, to arise in more posterior 220 
locations [80].  221 
2.1.10 Status of the surgical resection margins 222 
In one recent study [5], the status of the surgical resection margins together 223 
with the pN status were the strongest predictors of outcome in a logistic 224 
regression model based on 489 patients (Figure 1). Univariate analysis 225 
showed a marked difference in 5-year disease-specific survival for clear, close 226 
and involved margins (92%, 68% and 48%, respectively). Assessment of the 227 
resection margins should consider separately the mucosal margins, the 228 
submucosal / deep margin and the bone margins [68]. Involved or close 229 
mucosal margins may be more amenable to further surgery compared with 230 
involved submucosal / deep and bone margins, and mucosal margins are 231 
more easily observed during post-operative review. The current RCPath 232 
guidelines and minimum dataset [68] advises recording of margins of <1 mm 233 
as involved, 1-5 mm as close and > 5mm as clear. “Involved” margins are 234 
recorded as showing histological cut-through when tumour is detected at the 235 
actual margin.  236 
Since inadequate resection margins have such a profound effect on outcome, 237 
a detailed consideration of some of the pathological findings is worthwhile and 238 
may serve to alert surgeons and pathologists of potential high-risk sites and 239 
features. Inadequate mucosal margins are rare compared to close / involved 240 
submucosal / deep margins. In a study of 301 surgical resection specimens 241 
[81], only eleven cases showed an involved mucosal margin compared to 61 242 
cases with involved submucosal / deep soft tissue margins. Furthermore, 243 
there was a histological explanation for the inadequate mucosal margin in 244 
nine of the eleven cases. In six of these, cut-through of superficially invasive 245 
carcinoma that was not visible macroscopically was present. These tumours 246 
often showed a multifocal surface origin within a wider area of dysplasia. In a 247 
further three cases, a second synchronous primary tumour, not suspected 248 
clinically, was evident at the histological mucosal margin separated from the 249 
index tumour by non-dysplastic epithelium. Involved submucosal / deep 250 
margins were more frequent in the oropharynx and buccal mucosa (33% of 251 
cases) compared to floor of mouth and oral tongue (20% and 11%, 252 
respectively). The most frequent histological explanation of the involved soft 253 
tissue margin (seen in 39 of the 61 cases) was a non-cohesive growth pattern 254 
with individual tumour cells or tiny islands or cords forming the advancing 255 
front. A single streak of tumour or isolated satellite nodule accounted for 256 
eleven and six cases, respectively, with lymphovascular invasion and neural 257 
invasion accounting for three of the remaining five cases. The tumour had a 258 
circumscribed edge – growth pattern 2 [54, 55] – in only a single case.  An 259 
involved bone margin was seen in 10 of the 100 cases with pT4 status on 260 
account of bone involvement. Most of these cases also had an involved soft 261 
tissue / mucosal margins, and, hence, the involved bone margin was further 262 
evidence of the tumour’s unfavourable growth pattern.  263 
Guidelines are essential for accurate standardised reporting and the criteria 264 
for assessment recommended by the RCPath [68] are simple to use yet 265 
generally robust. Nevertheless, our experience suggests that a 5mm margin 266 
may still be inadequate in the case of a highly infiltrative tumour in which the 267 
tumour islands and individual cells are widely dispersed. Conversely, a 2-3mm 268 
margin may be adequate in a verrucous carcinoma with its characteristic 269 
pushing front or a conventional SCC with a cohesive, circumscribed growth 270 
pattern. Hence, decisions on post-operative management may need to 271 
consider some cases on an individual basis rather than apply a single, across-272 
the-board protocol. Brandwein-Gensler et al [67] concur with this view and 273 
state that a 5mm margin may not be effective in the presence of high risk 274 
histological features, namely pattern of invasion, perineural spread and 275 
minimal lymphocytic response. Tissue shrinkage during fixation and 276 
processing, which may be as high as 47% and varies depending on the type 277 
and consistency of the resected tissue [81, 82], is not taken into account, and 278 
this is an inherent weakness of the present recommendations. 279 
 280 
2.2 Lymph node metastases 281 
The UICC clinical and pathological N staging [4] is based on the number, 282 
laterality and size of nodal deposits. The RCPath minimum dataset [68] 283 
records these features, together with anatomical level(s) and extracapsular 284 
(extranodal) spread (ECS). The clinical, and in particular, the pathological N 285 
stage are major determinants of outcome [47, 48, 54, 69, 71, 73, 83]. As 286 
mentioned above, pN status was one of the two predictive factors in the best-287 
fit logistic regression model in one recent study [5] (Figure 1). Traditionally, 288 
lymph node metastasis was said to reduce survival by 50% [84]. However, 289 
evidence that ECS not metastasis per se accounts for the predictive value is 290 
accumulating from independent studies [5, 85-89]. Difficulties with defining 291 
and standardising the reporting of ECS need to be resolved before its 292 
inclusion in the UICC pathological staging procedure but several potential 293 
systems have been suggested [50]. Moreover, it appears that it is the 294 
presence of ECS, however minor, rather than the extent, that imparts the poor 295 
prognosis [85, 86]. Patients with more extensive (macroscopic) ECS tend to 296 
die within the first year after surgery while patients with ECS only detectable 297 
histologically tend to die within the second post-operative year [85]. Post 298 
operative radiotherapy to the neck may not improve the long-term survival [90] 299 
since many patients with ECS have multiple unfavourable histological features 300 
of their primary tumour and are highly likely to suffer intra-oral relapse [85]. 301 
Our current opinion is that ECS is a simple histological marker of an 302 
aggressive tumour. The fact that ECS can be present in association with small 303 
metastatic deposits of only 1mm (undetectable by palpation and current 304 
routine radiological imaging procedures) makes it a more powerful 305 
prognosticator than traditional markers such as size and number of nodal 306 
deposits which indicate tumour extent rather than aggressive behaviour.    307 
The prognostic importance of isolated tumour cells (<0.2mm), 308 
micrometastases (<2mm) and established metastases [4, 91] confined to the 309 
lymph node is uncertain. Woolgar [92] reported no differences in survival 310 
between patients with only micrometastasis and those with pN0 necks. In a 311 
further study [93] in which cytokeratin immunohistochemistry was utilised on 312 
all lymph nodes from dissections that were negative on routine staining, 313 
tumour cells were identified in one or more nodes in 50% of patients. Although 314 
neck recurrence was seen with increased frequency in the pN0 (mi) group [4], 315 
there were no overall differences in survival [93]. Serial sectioning and 316 
immunohistochemical staining are used in the setting of sentinel node biopsy 317 
procedures in an attempt to increase the probability of identifying positive 318 
nodes before proceeding to selective neck dissection. However, since the 319 
prognostic significance of micrometastases is uncertain, step-serial sectioning 320 
and the use of immunohistochemistry are not currently recommended in the 321 
pathological examination of routine neck dissection specimens [94].   322 
 323 
2.3 Distant (systemic) metastases 324 
Around 2-3% of oral cancer patients have clinically detectable distant 325 
systemic metastases at presentation [95]. Lung is the favoured site followed 326 
by bone (spine and ribs) and liver. A synchronous lung primary tumour should 327 
be considered in the differential diagnosis of an isolated lung metastasis. 328 
Surgery may be performed for palliative intent in patients with distant 329 
metastases. Even with chemoradiation, the prognosis remains poor. 330 
 331 
2.4 Pathological TNM stage 332 
This is a powerful prognosticator with a gradual decline in the 5-year disease 333 
specific survival for stages I-III followed by a steep drop for stage IV [5, 43, 47, 334 
71, 96, 97]. For example, in one recent oral cancer study [5], 5-year disease 335 
specific survival for stages I-III fell from 96-78% but survival for pstage IV was 336 
only 57%. Pathological N2/3 rather than pT4 accounted for the pstage IV 337 
status in the majority of cases.  338 
 339 
2.5 Field cancerisation, serial tumours  340 
Multiple primaries at the time of initial surgery or sequential in the post-341 
operative period are challenging problems especially in relation to clinical and 342 
pathological diagnosis, surgical planning and staging. It has long been 343 
recognised that oral cancer patients frequently develop multiple aetiologically-344 
related primary tumours mainly affecting the aerodigestive tract [98]. Second 345 
primary head and neck tumours occur in around 7-15% of patients [5, 99] and 346 
this risk appears cumulative with a 20-year risk and as high as 36% [100]. 347 
Survival from these is worse than for a comparable first primary [101] since 348 
treatment options are limited by the anatomical and physiological effects of 349 
the initial therapy. Histological evidence of dysplasia of mucosa peripheral to 350 
the index tumour in surgical resection specimens is a useful prognosticator 351 
particularly if smoking and drinking habits continue post-operatively.  352 
 353 
3 Post-surgical course including peri-operative 354 
complications, adjuvant treatment, local and regional 355 
and systemic relapse 356 
3.1 General considerations 357 
The post-operative course is related to multiple and varied factors ranging 358 
from age, co-morbidity, extent and length of surgery, type of reconstruction, 359 
and post-operative adjuvant therapy [102-106].  360 
Death intra or peri-operatively (<2 weeks from surgery) is reported in 3-4% of 361 
patients [102, 104, 106]. Alcoholism and peri-operative hypotension are two 362 
predictive factors for sudden death in the peri-operative period [106]. Other 363 
complications include wound dehiscence and infection which are reported in 364 
20% of cases [104]. Contributing factors for all complications including death 365 
are pre-existing co-morbidity, in particular, cardiovascular and respiratory 366 
disease; stage of disease; extent and timing of surgery, in particular if bilateral 367 
neck dissection is performed; alcoholism; tracheostomy; poor differentiation of 368 
tumour; and ECS [102-106]. In general, the factors reflect either a high-risk 369 
patient or a high-risk, that is, aggressive, tumour. 370 
Patients receiving post-operative radiotherapy have poorer overall and 371 
disease specific survival [5, 107], again reflecting adverse tumour 372 
characteristics. 373 
 374 
3.2 Local and regional relapse 375 
In the recent study by Rogers et al [5], the local recurrence rate was 10% and 376 
loco-regional recurrence rate 21%. Relapse in the neck tends to present 377 
earlier than an intra-oral recurrence [46] and may be due to growth of residual 378 
tumour in the operated field, or disease presenting in nodes outside the 379 
treated area. The former imparts a worse prognosis and is almost always 380 
associated with ECS at the time of original surgery.   381 
 382 
3.3 Distant (systemic) relapse 383 
As local and regional control of oral cancer has improved, distant metastases 384 
have been increasingly diagnosed with 5-25% and up to 50% of patients, 385 
respectively, having clinical and autopsy evidence of distant spread [108, 386 
109]. They are more commonly associated with increasing T, and, in particular 387 
N classification, developing in 17-51% of patients staged N2/3 at initial 388 
surgery [1109]. ECS and bilateral nodal metastases are particularly good 389 
predictors [108-110]. Most distant metastases are diagnosed within two years 390 
and affect the lungs, bone and liver in decreasing frequency. They are 391 
preceded by locoregional relapse in a high proportion of cases [110, 111] with 392 
around 20% appearing to represent slow growth of tumour disseminated early 393 
in the disease course and left behind after successful locoregional control.    394 
 395 
4      Molecular markers 396 
Studies have identified regions of genetic loss common to the vast majority of 397 
OSCC and also report a high incidence of LOH in aggressive tumours [112]. 398 
LOH at 2q, 3p, 8p, 9p, 11p and 18q have been correlated with poor outcome, 399 
particularly recurrence and decreased survival [112-114]. Aberrant p53 400 
expression as determined by immunohistochemistry and mutation has been 401 
correlated with larger number of metastases as well as decreased recurrence-402 
free and overall survival [115-117].  403 
Although of interest and of potential use in identifying more aggressive 404 
tumours, the aberrations themselves represent alterations in complex 405 
signalling pathways (cell cycle, proliferation, apoptosis) and as such are not 406 
amenable to targeted treatment.   407 
 408 
5      Recent trends  409 
Evaluation of outcome over a ten year period [5] has shown a significant 410 
improvement in both overall and disease-specific survival in patients treated 411 
between 2000-02 compared to 1992-5 (81% and 63% compared to 64% and 412 
46%, respectively). Small tumours at presentation, more favourable 413 
histological features, less extensive surgery with reduced use of free-flap 414 
reconstruction and neck dissection likely contributed to the improved outcome. 415 
In addition, more patients received a higher dosage of post-operative 416 
radiotherapy in the later period. It is likely that advances in anaesthesia and 417 
post-operative management have also contributed to the improved mortality 418 
rates. It is too early to assess the impact of the recent trend [118] to use 419 
induction chemotherapy prior to surgery. 420 
 421 
6 Future perspectives 422 
Further improvements in the outcome for patients with oral SCC almost 423 
certainly lie in the identification of molecular aberrations that are amenable to 424 
targeted therapy which will complement the currently available treatment 425 
options and in particular deal with the problem of microscopic residual 426 
disease. Epidermal growth factor receptor (EGFR) is the most promising 427 
candidate for therapeutic targeting due to its over expression in more than 428 
90% of tumours [119]. To date, clinical trials of anti-EGFR monoclonal 429 
antibodies including cetuximab have been largely confined to patients with 430 
advanced stage disease but some shown a satisfactory and consistent 431 
improvement in outcome [120]. Nevertheless, a retrospective, single institution 432 
review of 29 patients treated with cetuximab and radiotherapy compared with 433 
103 patients treated by conventional chemoradiotherapy showed no 434 
differences in survival although the authors comment that the optimal 435 
treatment regime has not yet been defined. [121].  436 
Additional ways of utilising molecular biology are to look for tumour specific 437 
changes around the periphery of a tumour in an attempt to identify minimal 438 
residual disease that is beyond even histological detection. Studies have 439 
correlated the presence of mutant p53 [122] and methylation of p16 and 440 
cytoglobin [123] in histologically clear marginal tissue with local recurrence. 441 
Identification of minimal residual disease at the molecular level may assist in 442 
planning adjuvant post-operative treatment, both conventional chemotherapy / 443 
radiotherapy and novel targeted therapy [124] as this becomes translated into 444 
routine clinical practice.  445 
Executive summary 446 
Oral Cancer 447 
 Rising incidence 448 
 5-year disease-specific survival of around 50% 449 
 Pathological staging of surgical resection specimens influences post-450 
operative management  451 
 452 
In surgically managed patients, outcome is determined by  453 
 General and clinical factors 454 
 Histopathological features of the surgical resection specimen 455 
 456 
General and clinical determinants of outcome include 457 
 Age 458 
 Gender 459 
 Race 460 
 Co-morbidity 461 
 Risk factors / lifestyle 462 
 Socio-economic circumstances 463 
 Psychological factors including support 464 
 Post-operative course 465 
 466 
Histopathological features are of over-riding importance and include 467 
features of the primary tumour, neck dissection(s), systemic (distant) 468 
metastases, pTNM stage, evidence of field cancerisation 469 
 Primary tumour site, T stage, pT stage, tumour dimensions, histological 470 
grade and invasive front characteristics, lymphovascular invasion, 471 
perineural invasion, skin involvement, histological sub-type, status of 472 
resection margins 473 
 Presence of cervical lymph node metastasis; number, laterality and 474 
size of metastatic deposits, extracapsular spread; N and pN stage  475 
 476 
Relapse may be local (intra-oral), regional (neck), locoregional, systemic 477 
(distant) 478 
 479 
Future developments will likely identify molecular aberrations for 480 
targeted therapy and the detection of “sub-microscopic” residual 481 
disease 482 
483 
  484 
 485 
486 
Table 1 
Histological subtypes of oral / oropharyngeal squamous cell 
carcinoma 
 
 
1. Verrucous carcinoma 
2. Carcinoma cuniculatum 
3. Papillary squamous cell carcinoma 
4. Adenoid (acantholytic) squamous cell carcinoma 
5. Adenosquamous carcinoma 
6. Basaloid squamous cell carcinoma 
7. Spindle cell carcinoma 
8. Giant cell (pleomorphic) carcinoma 
9. Undifferentiated carcinoma 
 487 
 488 
Figure 1 489 
Disease specific survival for 489 patients with oral SCC by pN status and 490 
closeness of resection margins. [This figure was published in Oral Oncology, 491 
in press, doi:10.1016/j.oraloncology.2008.05.008, Rogers SN, Brown JS, 492 
Woolgar JA et al, Survival following primary surgery for oral cancer, Copyright 493 
Elsevier (2008)]. 494 
 495 
 496 
Groups (patients in cohort) 497 
 A (n=180): Clear Margins & pN0  498 
 B (n=122): Clear margins & pN1 OR close margins & pN0 499 
 C (n=97):   Clear margins & pN2-3 OR close margins & pN1 OR involved margins & pN0 500 
 D (n=56):   Close margins & pN2-3 OR involved margins & pN1 501 
 E (n=34):   Involved margins & pN2-3 502 
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